CAH

AI Research

Cardinal Health Raises FY2026 EPS to $10.15-10.35 → 23-26% YoY Growth, All-Time High $229.88

Cardinal Health raised fiscal year 2026 non-GAAP EPS guidance to $10.15-10.35, implying 23-26% year-over-year growth driven by pharmaceutical distribution volumes and specialty business expansion, as the stock hit an all-time high of $229.88. Analyst consensus holds a Buy rating with an average price target of $249.27, suggesting approximately 8% additional upside from the recent high. Risks include pharmaceutical pricing pressure, generic drug deflation, and healthcare policy changes that could impact distribution margins.